摘要
目的 高效液相色谱法（HPLC）测定血浆中顺铂（DDP）含量，研究载顺铂磁性纳米药物在家兔体内的药动学特征及其相关药动学参数。方法 家兔12 只，随机分为2 组。分别于兔耳缘静脉注射3 mg·kg-1（按DDP含量计）剂量载顺铂磁性纳米药物和DDP，按设定时间于对侧耳缘动脉采血，通过改良HPLC法测定血浆中DDP浓度。以3P97药动学程序处理血浆药物浓度-时间数据，进行药动学分析。结果 本实验单剂量静注DDP在家兔体内的药动学特征符合二室模型，载顺铂磁性纳米药物则符合三室模型。主要动力学参数与DDP相比，载顺铂磁性纳米药物的清除率（CL）是DDP的0.620倍，t1/2α是DDP的1.579倍，t1/2β是DDP的0.552倍，Vd是DDP的1.845倍，血药浓度-时间曲线下面积（AUC ）是DDP的1.237倍。结论 实验结果表明，载顺铂磁性纳米药物经改良，提高了药物的稳定性，载顺铂磁性纳米药物改变了DDP的药动学特性。药动学参数表明，药物通过生物转化或排泄从体内消除加快，组织对药物的摄取量增加。
Abstract
OBJECTIVE To explore the pharmacokinetic characteristics and assess the safety of modified cisplatin（DDP） magnetic nano medicine. METHODS Twelve New Zealand rabbits were divided into 2 groups at random. DDP and magnetic nanomedicine （DDPmtnm） of 3 mg·kg-1 was administered by the vein of auris edge. The plasma concentration of DDP was detected by High Performance Liquid Chromatography （HPLC）. The detedted DDP concentration in plasma was analyzed by 3P97 software.RESULTS The pharmacokinetics of DDP was best described by a two-compartment model，whereas the DDP mtnm′s was described by a three-compartment model. As for the pharmacokinetic parameters，the clearance from blood，the distribution half life （t1/2α） ，the elimination half life（t1/2β） ，the apparent distribution volume（Vd ） and the area under curve （AUC） of DDPmtnm was 0.620，1.579，0.522，1.845， and 1.237 times of those of DDP， respectively.CONCLUSION The RESULTS show that the stability of the modified DDPmtnm is enhanced and the distribution characteristics of DDP in vivo is changed.The pharmacokinetic parameters of DDPmtnm indicate that the elimination of the drug from the body by biotransformation or excretion become much quicker and the uptake of the drug by the tissues increase as well.
关键词
磁性纳米药物 /
顺铂 /
高效液相色谱法 /
药动学
{{custom_keyword}} /
Key words
magnetic nanomedicine /
cisplatin /
HPLC /
pharmacokinetics
{{custom_keyword}} /
陈帅君 谢民强 徐雪青 沈辉 张宏征 万良财.
载顺铂磁性纳米药物药动学研究[J]. 中国药学杂志, 2011, 46(16): 1265-1268
CHEN Shui-jun;XIE Min-qing;XU Xue-qing;SHEN Hui;ZHNG Hong-zheng;WN Ling-ci.
Pharmacokinetic Study of Modified Cisplatin Magnetic Nanomedicine[J]. Chinese Pharmaceutical Journal, 2011, 46(16): 1265-1268
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SCHURIG J E，BRANDER W T，HAFTALEN J B，et al. In： Prestayko AWCrooke S T，Carter S K，eds. Cisplatin： Current Status and New Development［C］. New York： Academic Press，1980.
[2] ALEXIOU C，JURGONS R，SCHMID R J，et al. Magnetic drug targeting biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment［J］. J Drug Target，2003，11（3）： 139-149.
[3] XIE M Q，CHEN S J，XU X Q，et al. Preparation of two kinds of superparamagnetic carriers supported cis-platinum complexes and the comparison of their characteristics［J］. Chin Sci Bull（中国科学通报英文版），2006， 51（2）： 151-157.
[4] YU Y Q，WU M Z，MAO Y X，et al. HPLC Determination of cisplatin injection［J］. Chin Pharm J （中国药学杂志），1994，29（5）：296-297.
[5] CHEN S J，XIE M Q，WANG L， et al. Determination of cisplatin in plasma of rabbits by HPLC［J］. Chin Pharmacol Bull（中国药理学通报），2008，24（5）：692-695.
[6] XU F H，JIANG X T，ZHONG Y Q，et al. Pharmacokinetics of cisplatin albumin microsphere after embolizing in hapetic artery［J］. Chin Pharm J（中国药学杂志），1995，30（3）：144-147.
[7] WANG S L，CHEN D L，DING M Z. Study on distribution of cisplatin in rabbit after the administration of cisplatin implants implanted into rabbit tongue［J］. Chin Pharm J（中国药学杂志），2007，42（18）：1409-1414.
[8] CHEN S J，XIE M Q，WANG L，et al. The safety assessment of modified cis-platinum magnetic nanomedicine［J］. J China Pharm （中国药房）， 2008，19（25）：1941-1943.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(819 KB)
